Advisory Committee Research, Reports, and Announcements

The U.S. Food and Drug Administration, to assist in its mission to protect and promote the public health, uses committees and panels to obtain independent expert advice on scientific, technical, and policy matters. The public and Congress regularly show interest in these advisory committees (ACs), especially the screening for conflicts of interest and the use of waivers for some conflicts. Although the agency has taken a variety of steps to increase transparency and predictability of its ACs, FDA continues to seek opportunities to assess its advisory committee program for future improvement efforts.

Research and Reports

• FDA-TRACK Advisory Committees
• Errata, Fiscal Years 2016 through 2023 Annual Reports on FDA Advisory Committee Vacancies and Public Disclosures¹
• Fiscal Year 2013 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2014 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2015 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2016 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2017 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2018 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2019 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2020 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2021 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2022 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2023 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures
• Fiscal Year 2024 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures

 

1. 11During FY 2024, FDA received an inquiry that alerted us to certain discrepancies in our Advisory Committee Vacancies and Public Disclosures Report for past fiscal years. Upon review, FDA determined that some reports included a limited number of inaccurate figures in Table 2, primarily due to data entry and tabulation errors. The revised tables are included in the “Errata” report linked here. Please consult this document for updated Table 2 figures for the relevant reports.